Latest Administration News

Praemium Limited reported a 5.7% revenue increase to $110.5 million and a 21.1% jump in funds under administration to $77.9 billion for FY26, driven by strong high-net-worth segment growth and the integration of OneVue. The acquisition of Technotia Laboratories and a major technology restructure signal a sharpened focus on innovation and cost efficiency.

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

Queste Communications Ltd (ASX:QUE) posted a 66% increase in company-level profit for FY2026, but its consolidated entity, including Orion Equities (ASX:OEQ), saw earnings decline sharply amid weaker revenues and investment losses. No dividend was declared.

Orion Equities (ASX:OEQ) returned to profitability in FY26 with a $204,000 net profit, buoyed by a $400,000 uplift in investment property value. Despite a 7% dip in total revenue, net tangible asset backing per share edged up to $0.43, while no dividend was declared.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

BKI Investment Company has expanded its risk disclosure, outlining significant market, income, operational, and regulatory risks that could influence its financial outcomes and shareholder dividends.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

Foley Wines reported a 258% surge in net profit for FY2026 despite a 5.4% decline in bottled sales revenue, driven by a premiumisation strategy and cost controls.

Berkeley Energia reported a $8.7 million net loss for FY2026 while pushing forward with its Salamanca uranium project and maiden critical minerals resource at Conchas. The company continues a $1.25 billion ICSID arbitration claim against Spain over permitting delays.

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Constellation Technologies (ASX:CT1) reported a 5% revenue decline to $1.71 million and a $458,246 net loss for FY26, weighed down by delayed hardware deployments and increased expenses. Recurring subscription revenue grew 22%, reflecting ongoing customer engagement.